Helen Blair Simpson, MD, PhD

Rapastinel (GLYX-13) Effects in OCD

February 21, 2018

Read a study investigating the effects of rapastinel administration on 7 patients with OCD.

Omer Linkovski, Hanyang Shen, Jordana Zwerling, et al

Challenges in Testing Intranasal Ketamine in OCD

April 26, 2017

Reports have indicated that a single intravenous ketamine dose rapidly decreases OCD symptoms. These researchers planned a study of nasal ketamine administration for this purpose, but they quickly encountered...

Carolyn I. Rodriguez, Kyle A. B. Lapidus, Jordana Zwerling, et al

Letter to the Editor

Memantine in OCD

May 25, 2016

Ketamine may reduce OCD symptoms in some patients, but IV administration is undesirable. Learn whether oral memantine, another NMDA receptor antagonist, would be a good alternative.

Carolyn I. Rodriguez, Amanda Levinson, Jordana Zwerling, et al

Letter to the Editor

Can Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder? An Open-Label Trial

March 23, 2016

Carolyn I. Rodriguez, Michael Wheaton, Jordana Zwerling, et al

Original Research

Exposure and Response Prevention Helps Adults With Obsessive-Compulsive Disorder Who Do Not Respond to Pharmacological Augmentation Strategies

December 23, 2015

Carmen P. McLean, Laurie J. Zandberg, Page E. Van Meter, et al

Original Research

Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder

April 22, 2015

Edna B. Foa, Helen Blair Simpson, David Rosenfield, et al

Original Research

Treatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder

July 15, 2013

Samantha G. Farris, Carmen P. McLean, Page E. Van Meter, et al

Original Research

Six-Month Follow-Up of a Randomized Controlled Trial Augmenting Serotonin Reuptake Inhibitor Treatment With Exposure and Ritual Prevention for Obsessive-Compulsive Disorder

May 15, 2013

Edna B. Foa, Helen Blair Simpson, Michael R. Liebowitz, et al

Letter to the Editor

Patient Adherence to Cognitive-Behavioral Therapy Predicts Long-Term Outcome in Obsessive-Compulsive Disorder

September 15, 2012

Helen Blair Simpson, Sue M. Marcus, Allan Zuckoff, et al

Letter to the Editor

Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder

April 15, 2011

Carolyn I. Rodriguez, Lawrence S. Kegeles, Pamela Flood, et al

Original Research

Patient Preferences for Obsessive-Compulsive Disorder Treatment

November 15, 2010

Sapana R. Patel, Helen Blair Simpson

Letter to the Editor

Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder: An Open-Label Trial

September 15, 2010

Carolyn I. Rodriguez, James Bender Jr, Sue M. Marcus, et al

Rapastinel (GLYX-13) Effects in OCD

Challenges in Testing Intranasal Ketamine in OCD

Memantine in OCD

Can Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder? An Open-Label Trial

Exposure and Response Prevention Helps Adults With Obsessive-Compulsive Disorder Who Do Not Respond to Pharmacological Augmentation Strategies

Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder

Treatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder

Six-Month Follow-Up of a Randomized Controlled Trial Augmenting Serotonin Reuptake Inhibitor Treatment With Exposure and Ritual Prevention for Obsessive-Compulsive Disorder

Patient Adherence to Cognitive-Behavioral Therapy Predicts Long-Term Outcome in Obsessive-Compulsive Disorder

Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder

Patient Preferences for Obsessive-Compulsive Disorder Treatment

Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder: An Open-Label Trial

ELSEWHERE:

FOLLOW US:

Helen Blair Simpson, MD, PhD

Rapastinel (GLYX-13) Effects in OCD

Challenges in Testing Intranasal Ketamine in OCD

Memantine in OCD

Can Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder? An Open-Label Trial

Exposure and Response Prevention Helps Adults With Obsessive-Compulsive Disorder Who Do Not Respond to Pharmacological Augmentation Strategies

Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder

Treatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder

Six-Month Follow-Up of a Randomized Controlled Trial Augmenting Serotonin Reuptake Inhibitor Treatment With Exposure and Ritual Prevention for Obsessive-Compulsive Disorder

Patient Adherence to Cognitive-Behavioral Therapy Predicts Long-Term Outcome in Obsessive-Compulsive Disorder

Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder

Patient Preferences for Obsessive-Compulsive Disorder Treatment

Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder: An Open-Label Trial

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles